Patient characteristics
| . | Total N = 417 . |
|---|---|
| Age at transplant, y | 44 (32-55) |
| <40 | 168 (40.3) |
| 40-49 | 94 (22.5) |
| 50-59 | 91 (21.8) |
| ≥60 | 64 (15.3) |
| Sex | |
| Male | 253 (60.7) |
| Female | 164 (39.3) |
| ECOG PS | |
| 0-1 | 381 (91.4) |
| ≥2 | 34 (8.2) |
| HCT-CI | |
| 0-2 | 363 (87.1) |
| ≥3 | 48 (11.5) |
| CMV-Ab | |
| Negative | 70 (16.8) |
| Positive | 336 (80.6) |
| WBC at diagnosis, per 109/L | 9.50 (3.33-39.06) |
| Cytogenetics of MPAL | |
| BCR::ABL1 fusion | 82 (19.7) |
| KMT2A rearrangement | 9 (2.2) |
| Cytogenetic risk category (AML) | |
| Favorable | 0 (0.0) |
| Intermediate | 121 (29.0) |
| Poor | 112 (26.9) |
| Unevaluable | 184 (44.1) |
| Disease status at transplant | |
| CR1 | 276 (66.2) |
| CR2 | 27 (6.5) |
| CR3 or higher | 2 (0.5) |
| nCR | 98 (23.5) |
| Diagnosis to SCT, mo | 5.8 (4.6-7.8) |
| Sex mismatch | |
| Match | 211 (50.6) |
| Male to female | 88 (21.1) |
| Female to male | 103 (24.7) |
| ABO mismatch | |
| Matched | 198 (47.5) |
| Minor mismatch | 99 (23.7) |
| Major mismatch | 78 (18.7) |
| Major-minor mismatch | 39 (9.4) |
| HLA mismatch | |
| HLA-matched | 169 (40.5) |
| HLA-mismatched | 240 (57.6) |
| Conditioning | |
| MAC | 315 (75.5) |
| RIC | 100 (24.0) |
| Conditioning, TCI category | |
| High | 307 (73.6) |
| Intermediate | 92 (22.1) |
| Low | 15 (3.6) |
| TBI | |
| TBI no | 89 (21.3) |
| TBI yes | 326 (78.2) |
| Graft source | |
| Rel-BM | 26 (6.2) |
| Rel-PBSC | 87 (20.9) |
| UR-BM | 134 (32.1) |
| UR-PBSC | 23 (5.5) |
| UR-CB | 146 (35.0) |
| GVHD prophylaxis | |
| CyA-based | 113 (27.1) |
| Tac-based | 300 (71.9) |
| Transplant year | |
| 2008-2015 | 218 (52.3) |
| 2016-2022 | 199 (47.7) |
| . | Total N = 417 . |
|---|---|
| Age at transplant, y | 44 (32-55) |
| <40 | 168 (40.3) |
| 40-49 | 94 (22.5) |
| 50-59 | 91 (21.8) |
| ≥60 | 64 (15.3) |
| Sex | |
| Male | 253 (60.7) |
| Female | 164 (39.3) |
| ECOG PS | |
| 0-1 | 381 (91.4) |
| ≥2 | 34 (8.2) |
| HCT-CI | |
| 0-2 | 363 (87.1) |
| ≥3 | 48 (11.5) |
| CMV-Ab | |
| Negative | 70 (16.8) |
| Positive | 336 (80.6) |
| WBC at diagnosis, per 109/L | 9.50 (3.33-39.06) |
| Cytogenetics of MPAL | |
| BCR::ABL1 fusion | 82 (19.7) |
| KMT2A rearrangement | 9 (2.2) |
| Cytogenetic risk category (AML) | |
| Favorable | 0 (0.0) |
| Intermediate | 121 (29.0) |
| Poor | 112 (26.9) |
| Unevaluable | 184 (44.1) |
| Disease status at transplant | |
| CR1 | 276 (66.2) |
| CR2 | 27 (6.5) |
| CR3 or higher | 2 (0.5) |
| nCR | 98 (23.5) |
| Diagnosis to SCT, mo | 5.8 (4.6-7.8) |
| Sex mismatch | |
| Match | 211 (50.6) |
| Male to female | 88 (21.1) |
| Female to male | 103 (24.7) |
| ABO mismatch | |
| Matched | 198 (47.5) |
| Minor mismatch | 99 (23.7) |
| Major mismatch | 78 (18.7) |
| Major-minor mismatch | 39 (9.4) |
| HLA mismatch | |
| HLA-matched | 169 (40.5) |
| HLA-mismatched | 240 (57.6) |
| Conditioning | |
| MAC | 315 (75.5) |
| RIC | 100 (24.0) |
| Conditioning, TCI category | |
| High | 307 (73.6) |
| Intermediate | 92 (22.1) |
| Low | 15 (3.6) |
| TBI | |
| TBI no | 89 (21.3) |
| TBI yes | 326 (78.2) |
| Graft source | |
| Rel-BM | 26 (6.2) |
| Rel-PBSC | 87 (20.9) |
| UR-BM | 134 (32.1) |
| UR-PBSC | 23 (5.5) |
| UR-CB | 146 (35.0) |
| GVHD prophylaxis | |
| CyA-based | 113 (27.1) |
| Tac-based | 300 (71.9) |
| Transplant year | |
| 2008-2015 | 218 (52.3) |
| 2016-2022 | 199 (47.7) |
Continuous variables are presented as median (IQR); categorical variables as number (%).
BM, bone marrow; CB, cord blood; CMV-Ab, cytomegalovirus antibody; CyA, cyclosporin A; HCT-CI, hematopoietic cell transplantation–specific comorbidity index; MAC, myeloablative conditioning; PBSC, peripheral blood stem cell; Rel, related; RIC, reduced-intensity conditioning; SCT, stem cell transplant; Tac, tacrolimus; TBI, total body irradiation; UR, unrelated; WBC, white blood cell.